XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2021
Sep. 30, 2020
Current Assets:    
Cash and cash equivalents $ 115,663,976 $ 13,859,748
Prepaid expenses 1,271,395 122,237
Total Current Assets 116,935,371 13,981,985
Property and equipment, net 7,754 1,577
Operating lease right-of-use asset, net 864,865 986,204
Other Assets:    
Deposits 38,062 57,093
In-process research and development 19,400,000 19,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 28,784,858 28,803,889
Total Assets 146,592,848 43,773,655
Current Liabilities:    
Accounts payable 1,354,664 1,856,235
Accrued expenses 366,736 164,040
Accrued compensation 1,539,813 1,654,919
Accrued interest 1,974 89,970
Notes payable – related parties 172,970
Note payable – paycheck protection program 164,583
Operating lease liability 172,540 158,999
Total Current Liabilities 3,600,310 4,097,133
Note payable – paycheck protection program 164,583
Deferred tax liability 4,985,800 4,985,800
Operating lease liability – non current 724,785 855,471
Total Liabilities 9,310,895 10,102,987
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 145,979,429 and 55,576,996 shares issued and outstanding at June 30, 2021 and September 30, 2020, respectively 145,979 55,577
Additional paid-in capital 227,622,330 104,208,958
Accumulated deficit (91,086,736) (70,593,867)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 136,681,573 33,670,668
Non-controlling interest 600,380
Total Equity 137,281,953 33,670,668
Total Liabilities and Equity $ 146,592,848 $ 43,773,655